africa.com
africa.com
Health Reform Needs More Than Public-Private Partnerships. It Needs New Rules And Better-Designed Systems
ContributedFeatures & Opinion

Health Reform Needs More Than Public-Private Partnerships. It Needs New Rules And Better-Designed Systems

By Dr Jessica Hamuy Blanco·Edited by SG Editor·
ContributedThis article was contributed by Dr Jessica Hamuy Blanco. The views expressed are the author’s own.Our editorial standards

By Dr Jessica Hamuy Blanco, Product and Clinical Risk Executive, Dis-Chem

As global health funding comes under pressure, the challenge is not simply to decide who should deliver healthcare, but to redesign the incentives that determine whether our economies and institutions produce better health.

It is an interesting time to think about the future of health. Global health systems are under mounting pressure, traditional funding models are being challenged, and countries are asking urgent questions about sovereignty, sustainability and dependence. Institutions are reconsidering their roles, while a fundamental question emerges: are the structures that brought us this far capable of delivering what comes next?

I recently visited Geneva, the centre of global health, already thinking about the role of the private sector in health reform and how public and private institutions might work together to expand access to quality healthcare. I left thinking about something more fundamental.

Before deciding how these sectors should collaborate, we need to understand what each does well, what incentives drive its decisions, and whether those incentives support better health. Otherwise, public-private partnership risks becoming a convenient phrase for bringing different actors together without changing the conditions that determine what they can achieve.

The real challenge is to build systems in which creating both health and economic value are more consistently aligned.

We measure the economic value of health but why not the health value of our economies?

The economic case for better health is well established. Healthier populations can be more productive, participate more fully in economic life and face less financial hardship from illness. Prevention can reduce avoidable costs and support sustainable development. Yet we rarely ask the inverse question: how effectively does our economy produce health?

The economy does more than provide the environment in which healthcare systems operate. Labour markets, taxation, social protection, commercial practices and income distribution all influence who become sick, who can access care and who has the resources to recover.

Markets do not naturally optimise for population health. They respond to incentives shaped by what is profitable, measurable and affordable.

Commercial success and population health are therefore not synonymous. Products that contribute to ill health can be highly profitable. Communities with the greatest healthcare needs may have the least purchasing power. And the organisation paying for prevention may not be the one that ultimately benefits from it. When costs and benefits fall on different parties, even interventions that make economic sense for society can struggle to attract investment.

These are structural challenges that shape what gets funded, developed and delivered. Addressing them does not require an anti-market position. It requires understanding where markets create value, where they fail to account for it, and where policy must change the incentives.

Why health leaders need to understand the business of health

My perspective has evolved through different stages of my career.

I began as a medical doctor. Clinical medicine teaches you to encounter health systems at their most human: one patient at a time. System failure becomes tangible when someone needs care that is unavailable, unaffordable or delayed.

Academic research added another lens, teaching me to interrogate assumptions, examine evidence and understand underlying mechanisms.

Today, working in private-sector healthcare, I am deliberately developing my commercial thinking. I see this not as a departure from my commitment to improving access to quality healthcare, but as essential to achieving it.

An intervention can be clinically excellent and evidence-based yet still fail to change a health system. It must also be affordable, financeable and operationally feasible. Decision-makers must understand its value, people must be able to use it, and its economics must support sustainable scale.

Evidence alone does not guarantee adoption. Clinical value does not automatically translate into a viable business model, and success in a pilot does not guarantee success at scale.

Health reform therefore requires leaders who can bring clinical expertise, research, operational capability and commercial thinking into the same conversation. They must understand where these perspectives reinforce one another and where they conflict.

Not every tension can be resolved through a new business model. Some challenges require regulation, redistribution or public provision. The objective has become more sophisticated about how different players interact, identifying the right mechanism for each problem.

Partnership is not the same as alignment

Public-private partnership is an important part of health reform. Governments bring regulatory authority and responsibility for population health. Global institutions coordinate across borders and establish norms. Academia generates and challenges evidence. Private enterprise brings capital, technology, innovation and the ability to scale.

But every sector has limitations. Governments can struggle with fragmentation and implementation. Global institutions can become disconnected from delivery. Academia can produce evidence that never changes practice. Markets can efficiently optimise for outcomes that have little relationship to wider societal value.

Bringing these actors together does not automatically overcome these weaknesses or align their interests. Partnerships can fail even when participants are competent and act rationally within their own incentives. Sometimes, the problem lies not with the participants but with the system itself.

Health reform therefore needs more than collaboration. It needs architecture: the deliberate design of rules, financing arrangements, institutions and business models that determine what collaboration produces.

We must move beyond asking who should participate to asking what each actor is rewarded for, who carries the risk, who captures the value and who remains excluded.

Prevention will remain underfunded until we change the economics

Health systems have long struggled to shift resources from treating disease towards preventing it. Prevention often delivers benefits over years, while budgets are allocated annually. Its financial returns may also accrue to an organisation different from the one making the initial investment.

A business may invest in employee health while another payer benefits from reduced healthcare costs. A government may fund an intervention whose benefits emerge beyond its current planning cycle. An insurer may pay for prevention while another insurer benefits when a member changes plans.

In each case, the collective benefit can exceed the return available to the individual investor.

Sustained investment in prevention requires financing models that account for these long-term, distributed benefits. This could involve better coordination between governments, employers, insurers and healthcare providers, alongside payment models that reward improved health outcomes rather than simply the volume of services delivered.

The same principle applies to access. Those with the greatest health needs are often least able to pay. Private capital will not consistently reach underserved populations without viable models that account for affordability and risk.

Governments must therefore act not only as funders and regulators, but also as market shapers. Through purchasing decisions, subsidies, risk-sharing arrangements and health financing, they can create conditions in which socially valuable solutions become investable, sustainable and scalable.

The goal is not to remove commercial incentives from healthcare, but to make them work in ways that better serve public health. Where commercial capability expands access and accelerates innovation, it should be encouraged. Where commercial incentives conflict with population health, regulation and public accountability are essential.

The distinction is not between public and private. It is between arrangements that create value for society and those that do not.

Global health must move from dependence towards capability

These questions become more urgent as global health funding comes under pressure. Institutions face difficult choices, established funding arrangements are changing, and there are legitimate concerns about what could be lost. Disruption should not be romanticised, nor should we assume it will automatically produce better systems.

But it does create an opportunity to reconsider how global health is organised and how countries can build greater capacity to finance and deliver healthcare themselves.

Global institutions should focus on functions that genuinely require international cooperation: setting norms, coordinating across borders, supporting research and other global public goods, and helping countries strengthen their capabilities.

At the same time, sustainable reform must strengthen national institutions and domestic health systems rather than perpetuate dependence on external financing and delivery.

Governments need greater clarity about what they must finance, provide and regulate, and where private enterprise can extend their capabilities. The objective is not to maximise public or private provision, but to build health systems that improve outcomes, expand access and remain financially and operationally sustainable.

Resource scarcity makes these choices more consequential. When funding is limited, poorly designed incentives and inefficient allocation become even more costly.

The future belongs to health leaders who can navigate both worlds

I do not believe governments alone can deliver the health systems we need, nor do I believe markets will spontaneously produce them. Simply bringing representatives of both together and calling it partnership will not be enough.

We must become more deliberate about the relationship between health and economic value, treating population health not merely as a cost to manage, but as an outcome our institutions, policies and markets should be designed to produce.

Some interventions can create compelling commercial opportunities while delivering public value. Others will require public financing, collective action or regulation because markets will not adequately meet the need. Effective health systems must accommodate both.

For me, this is increasingly the work of health leadership: moving between clinical practice, evidence, operations and commercial strategy without assuming that any one perspective has all the answers.

The challenge is not to eliminate the tension between public purpose and commercial capability, but to understand it well enough to design better systems around it.

The future of health will depend not only on how much we spend, which technologies we develop or which institutions we preserve. It will also depend on the incentives we create, the capabilities we build and how economic value is generated and distributed.

If we want healthier populations, we must design economies and health systems that produce health. That is more complicated than partnership. It is also far more consequential.

About the author

Dr Jessica Hamuy Blanco

Product and Clinical Risk Executive, Dis-Chem